8-K: Veru Inc. Amends Forbearance Agreement with Onconetix, Inc., Extending Debt Maturity and Modifying Payment Terms

Veru Inc. has amended its forbearance agreement with Onconetix, Inc., extending the maturity dates of two promissory notes and modifying payment terms to facilitate repayment.

Summary

• Veru Inc. has entered into an amended forbearance agreement with Onconetix, Inc. regarding two promissory notes totaling $10 million.
• The agreement extends the forbearance period for a $5 million note due April 19, 2024, to the earlier of March 31, 2025, or an event of default.
• The maturity date for a second $5 million note due September 30, 2024, has been extended to the earlier of June 30, 2025, or an event of default.
• Monthly payments from Onconetix to Veru will increase to 25% of certain cash receipts, up from 15%, starting October 20, 2024.
• Veru will also receive 20% of net proceeds from certain financing or other transactions by Onconetix, up from 10%, for transactions after September 19, 2024.
• Interest on the second note will accrue at 10% per annum starting October 1, 2024.
• If both notes are repaid in cash by December 31, 2024, the principal balance of the second note will be reduced from $5 million to $3.5 million.

Sentiment

Score: 4

Explanation: The document indicates a distressed financial situation for Onconetix, requiring a forbearance agreement. While the agreement provides a path for repayment, the risk of default remains, and the terms are not particularly favorable for Veru. The sentiment is therefore negative.

Positives

• The extension of the maturity dates provides Onconetix with more time to repay the debt.
• Increased payment percentages from cash receipts and financing activities will accelerate debt repayment.
• The potential reduction in the principal of the September 2024 note provides an incentive for early repayment.
• The agreement ensures that Veru will receive payments from Onconetix's revenue streams and financing activities.

Negatives

• There is no guarantee that Veru will receive any payments under the amended agreement.
• There is a risk of future default by Onconetix on its payment obligations.
• The agreement relies on Onconetix's ability to generate revenue and secure financing.
• The agreement includes a cross-default clause, meaning a default on one note triggers a default on the other.

Risks

• Onconetix may not generate sufficient cash receipts to meet the required monthly payments.
• Onconetix may not be able to secure financing or complete transactions that would trigger the 20% payment to Veru.
• There is a risk of an event of default, which would accelerate the repayment obligations.
• The agreement relies on the financial stability and operational success of Onconetix.

Future Outlook

The agreement provides a framework for Onconetix to repay its debt to Veru, but the actual outcome depends on Onconetix's financial performance and ability to generate revenue and secure financing. There is no guarantee of repayment.

Management Comments

• The agreement has been negotiated in good faith.
• The forbearance by Holder as provided herein shall result in a direct and substantial benefit to Borrower.

Industry Context

This type of agreement is common in situations where a borrower is facing financial difficulties and needs more time to repay its debt. It is a way for the lender to avoid immediate default while providing the borrower with a path to repayment. The agreement is specific to the relationship between Veru and Onconetix and does not necessarily reflect broader industry trends.

Comparison to Industry Standards

• Forbearance agreements are common in distressed debt situations, but the specific terms, such as the increased payment percentages and the potential principal reduction, are specific to this agreement.
• The 10% interest rate on the September 2024 note is within the range of interest rates for similar types of debt, but the specific rate depends on the risk profile of the borrower.
• The agreement is similar to other debt restructuring agreements where the lender provides more time for repayment in exchange for increased payments or other concessions.

Stakeholder Impact

• Shareholders of Veru are exposed to the risk of non-payment by Onconetix.
• Onconetix's creditors are impacted by the restructuring of the debt.
• Onconetix's employees may be affected by the company's financial situation.

Next Steps

• Onconetix needs to make monthly payments to Veru based on cash receipts starting October 20, 2024.
• Onconetix needs to make payments to Veru based on proceeds from financing or other transactions.
• Veru will monitor Onconetix's compliance with the terms of the agreement.
• Veru will assess whether to convert the Series A Preferred Stock to common stock.

Key Dates

Keywords

forbearance agreement, promissory notes, debt restructuring, Onconetix, Veru Inc., maturity extension, payment terms, default, financing, cash receipts